Fibrin clot structure and function: A role in the pathophysiology of arterial and venous thromboembolic diseases

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 12, 2011, Pages

  Undas, Anetta ^a,b   Ariëns, Robert A S ^c  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

coagulation; fibrin; fibrinolysis; thrombolysis; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; ARGATROBAN; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5 LEIDEN; DABIGATRAN; DANAPAROID; FIBRIN; FONDAPARINUX; GEMFIBROZIL; HEPARIN; HIRULOG; LEPIRUDIN; LIPOPROTEIN A; METFORMIN; PROTHROMBIN; QUINAPRIL; RIVAROXABAN; SIMVASTATIN; THROMBIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY THROMBOSIS; BLOOD FLOW; BRAIN ISCHEMIA; CHROMOSOME 16; CHROMOSOME 17; CHROMOSOME 4; CHROMOSOME 5; CHROMOSOME 6; CHROMOSOME 9; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DIABETES CONTROL; DIABETES MELLITUS; DRUG MECHANISM; FIBRIN CLOT; FIBRINOLYSIS; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; QUANTITATIVE TRAIT LOCUS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SMOKING CESSATION; THROMBOCYTE ACTIVATION; VENOUS THROMBOEMBOLISM;

FIBRIN; HUMANS; OXIDATIVE STRESS; PLATELET ACTIVATION; RISK FACTORS; THROMBIN; THROMBOEMBOLISM; THROMBOSIS;

EID: 81755161511     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.230631     Document Type: Review

References (141)

1. Pratt KP, Côté HC, Chung DW, Stenkamp RE, Davie EW. The primary fibrin polymerization pocket: three-dimensional structure of a 30-kDa C-terminal gamma chain fragment complexed with the peptide Gly-Pro-Arg-Pro. Proc Natl Acad Sci USA. 1997;94:7176-7181.
2. Yang Z, Mochalkin I, Doolittle RF. A model of fibrin formation based on crystal structures of fibrinogen and fibrin fragments complexed with synthetic peptides. Proc Natl Acad Sci USA. 2000;97:14156-14161. (Pubitemid 32016546)
3. Henschen-Edman AH. Fibrinogen non-inherited heterogeneity and its relationship to function in health and disease. Ann N Y Acad Sci. 2001;936:580-593. (Pubitemid 32613944)
4. Burton RA, Tsurupa G, Medved L, Tjandra N. Identification of an ordered compact structure within the recombinant bovine fibrinogenαC-domain fragment by NMR. Biochemistry. 2006;45:2257-2266. (Pubitemid 43271325)
5. Tsurupa G, Hantgan RR, Burton RA, Pechik I, Tjandra N, Medved L. Structure, stability, and interaction of the fibrin(ogen)αC-domains. Biochemistry. 2009;48:12191-12201.
6. Veklich YI, Gorkun OV, Medved LV, Nieuwenhuizen W, Weisel JW. Carboxyl-terminal portions of theαChains of fibrinogen and fibrin: localization by electron microscopy and the effects of isolatedαC fragments on polymerization. J Biol Chem. 1993;268:13577-13585. (Pubitemid 23307788)
7. Riedel T, Suttnar J, Brynda E, Houska M, Medved L, Dyr JE. Fibrinopeptides A and B release in the process of surface fibrin formation. Blood. 2011;117:1700-1706.
8. Gorkun OV, Veklich YI, Medved LV, Henschen AH, Weisel JW. Role of theαC domains of fibrin in clot formation. Biochemistry. 1994;33: 6986-6997.
9. Collet JP, Moen JL, Veklich YI, Gorkun OV, Lord ST, Montalescot G, Weisel JW. TheαC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis. Blood. 2005;106:3824-3830. (Pubitemid 41739019)
10. Houser JR, Hudson NE, Ping L, O'Brien ET III, Superfine R, Lord ST, Falvo MR. Evidence thatαC region is origin of low modulus, high extensibility, and strain stiffening in fibrin fibers. Biophys J. 2010;99: 3038-3047.
11. Lim BB, Lee EH, Sotomayor M, Schulten K. Molecular basis of fibrin clot elasticity. Structure. 2008;16:449-459.
12. Liu W, Carlisle CR, Sparks EA, Guthold M. The mechanical properties of single fibrin fibers. J Thromb Haemost. 2010;8:1030-1036.
13. Brown AE, Litvinov RI, Discher DE, Purohit PK, Weisel JW. Multiscale mechanics of fibrin polymer: gel stretching with protein unfolding and loss of water. Science. 2009;325:741-744.
14. Ryan EA, Mockros LF, Stern AM, Lorand L. Influence of a natural and a synthetic inhibitor of factor XIIIa on fibrin clot rheology. Biophys J. 1999;77:2827-2836. (Pubitemid 29519525)
15. Collet JP, Shuman H, Ledger RE, Lee S, Weisel JW. The elasticity of an individual fibrin fiber in a clot. Proc Natl Acad Sci USA. 2005;102: 9133-9137. (Pubitemid 40923529)
16. Standeven KF, Carter AM, Grant PJ, Weisel JW, Chernysh I, Masova L, Lord ST, Ariëns RA. Functional analysis of fibrin gamma-chain crosslinking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. Blood. 2007;110:902-907. (Pubitemid 47267427)
17. Gaffney PJ, Whitaker AN. Fibrin crosslinks and lysis rates. Thromb Res. 1979;14:85-94. (Pubitemid 9108083)
18. Chen R, Doolittle RF. Gamma-gamma cross-linking sites in human and bovine fibrin. Biochemistry. 1971;10:4487-4491.
19. Spraggon G, Everse SJ, Doolittle RF. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature. 1997;389:455-462. (Pubitemid 27435313)
20. Ichinose A, Tamaki T, Aoki N. Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin. FEBS Lett. 1983;153:369-371. (Pubitemid 13114027)
21. Kimura S, Aoki N. Cross-linking site in fibrinogen forβ 2-plasmin inhibitor. J Biol Chem. 1986;261:15591-15595. (Pubitemid 17208788)
22. Ritchie H, Lawrie LC, Crombie PW, Mosesson MW, Booth NA. Crosslinking of plasminogen activator inhibitor 2 andβ 2-antiplasmin to fibrin(ogen). J Biol Chem. 2000;275:24915-24920. (Pubitemid 30626598)
23. Valnickova Z, Enghild JJ. Human procarboxypeptidase U, or thrombinactivable fibrinolysis inhibitor, is a substrate for transglutaminases: evidence for transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem. 1998;273:27220-27224. (Pubitemid 28500432)
24. Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin Thromb Hemost. 2009;35:426-438.
25. Levin EG, Marzec U, Anderson J, Harker LA. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest. 1984;74:1988-1995. (Pubitemid 15197340)
26. Thorsen S. The mechanism of plasminogen activation and the variability of the fibrin effector during tissue-type plasminogen activator-mediated fibrinolysis. Ann N Y Acad Sci. 1992;667:52-63. (Pubitemid 23061563)
27. Schneider M, Nesheim M. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J Biol Chem. 2004;279:13333-13339. (Pubitemid 38468855)
28. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J. 1990;9:467-474.
29. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood. 1996;88:2093-2100. (Pubitemid 26307911)
30. Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem. 1992;267:24259-24263.
31. Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arterioscler Thromb Vasc Biol. 2011;31:494-499.
32. Longstaff C, Thelwell C, Williams SC, Silva MM, Szabó L, Kolev K. The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies. Blood. 2011;117:661-668.
33. Collet JP, Montalescot G, Lesty C, Weisel JW. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res. 2002;90:428-434. (Pubitemid 34633912)
34. Dunn EJ, Ariëns RA, de Lange M, Snieder H, Turney JH, Spector TD, Grant PJ. Genetics of fibrin clot structure: a twin study. Blood. 2004; 103:1735-1740. (Pubitemid 38268966)
35. Carter AM, Cymbalista CM, Spector TD, Grant PJ. Heritability of clot formation, morphology, and lysis: the EuroCLOT Study. Arterioscler Thromb Vasc Biol. 2007;27:2783-2789. (Pubitemid 350158937)
36. Williams FM, Carter AM, Kato B, Falchi M, Bathum L, Surdulescu G, Kyvik KO, Palotie A, Spector TD, Grant PJ. Identification of quantitative trait loci for fibrin clot phenotypes: the EuroCLOT Study. Arterioscler Thromb Vasc Biol. 2009;29:600-605.
37. Standeven KF, Uitte de Willige S, Carter AM, Grant PJ. Heritability of clot formation. Semin Thromb Haemost. 2009;35:458-467.
38. Kant JA, Fornace AJ Jr, Saxe D, Simon MI, McBride OW, Crabtree GR. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci USA. 1985;82:2344-2348. (Pubitemid 15064484)
39. Yu S, Sher B, Kudryk B, Redman CM. Fibrinogen precursors: order of assembly of fibrinogen chains. J Biol Chem. 1984;259:10574-10581. (Pubitemid 14064160)
40. de Moerloose P, Boehlen F, Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost. 2010;36:7-17.
41. Lim BC, Ariëns RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet. 2003;361:1424-1431. (Pubitemid 36515043)
42. Ajjan R, Lim BC, Standeven KF, Harrand R, Dolling S, Phoenix F, Greaves R, Abou-Saleh RH, Connell S, Smith DA, Weisel JW, Grant PJ, Ariëns RA. Common variation in the C-terminal region of the fibrinogen-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood. 2008;111:643-650.
43. Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariëns RA. Functional analysis of the fibrinogen ÁThr312Ala polymorphism: effects on fibrin structure and function. Circulation. 2003;107: 2326-2330. (Pubitemid 36578503)
44. Carter AM, Catto AJ, Grant PJ. Association of-fibrinogen Thr312Ala polymorphism with post-stroke mortality in subjects with atrial fibrillation. Circulation. 1999;99:2423-2426. (Pubitemid 29218238)
45. Wolfenstein-Todel C, Mosesson MW. Human plasma fibrinogen heterogeneity: evidence for an extended carboxyl-terminal sequence in a normal gamma chain variant (α). Proc Natl Acad Sci USA. 1980;77: 5069-5073. (Pubitemid 11195509)
46. Cooper AV, Standeven KF, Ariëns RA. Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure. Blood. 2003;102: 535-540. (Pubitemid 36841972)
47. Gersh KC, Nagaswami C, Weisel JW, Lord ST. The presence ofαChain impairs fibrin polymerization. Thromb Res. 2009;124:356-363.
48. Ariëns RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and effects cross-linked fibrin structure. Blood. 2000;96: 988-995. (Pubitemid 30616865)
49. Trumbo TA, Maurer MC. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation. J Biol Chem. 2000;275:20627-20631. (Pubitemid 30457648)
50. Balogh I, Szôke G, Kárpáti L, Wartiovaara U, Katona E, Komáromi I, Haramura G, Pfliegler G, Mikkola H, Muszbek L. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood. 2000;96:2479-2486.
51. Vokó Z, Bereczky Z, Katona E, Adány R, Muszbek L. Factor XIII Val34Leu variant protects against coronary artery disease: a meta-analysis. Thromb Haemost. 2007;97:458-463. (Pubitemid 46437809)
52. Wells PS, Anderson JL, Scarvelis DK, Doucette SP, Gagnon F. Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis. Am J Epidemiol. 2006;164:101-109. (Pubitemid 43992174)
53. Wolberg AS, Monroe DM, Roberts HR, Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood. 2003;101: 3008-3013. (Pubitemid 36857988)
54. Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Aslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta. 1989;997:96-110. (Pubitemid 19178601)
55. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol. 2005;131:645-655. (Pubitemid 43899632)
56. Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood. 1996;88:3815-3823. (Pubitemid 26383103)
57. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost. 2009;7(suppl 1):301-304.
58. Meltzer ME, Lisman T, Doggen CJ, de Groot PG, Rosendaal FR. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med. 2008;5:e97.
59. Mazoyer E, Ripoll L, Gueguen R, Tiret L, Collet JP, dit Sollier CB, Roussi J, Drouet L. FITENAT Study Group. Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distribution. Blood Coagul Fibrinolysis. 2009;20:503-510.
60. Campbell RA, Overmyer KA, Bagnell R, Wolberg AS. Cellular procoagulant activity dictates clot structure and stability as a function of distance from the cell surface. Arterioscler Thromb Vasc Biol. 2008;28: 2247-2254.
61. Campbell RA, Overmyer KA, Selzman CH, Sheridan BC, Wolberg AS. Contributions of extravascular and intravascular cells to fibrin network formation. Blood. 2009;114:4886-4896.
62. Gersh KC, Edmondson KE, Weisel JW. Flow rate and fibrin fiber alignment. J Thromb Haemost. 2010;8:2826-2828.
63. Campbell RA, Aleman M, Gray LD, Falvo MR, Wolberg AS. Flow profoundly influences fibrin network structure: implications for fibrin formation and clot stability in haemostasis. Thromb Haemost. 2010;104: 1281-1284.
64. Neeves KB, Illing DA, Diamond SL. Thrombin flux and wall shear rate regulate fibrin fiber deposition state during polymerization under flow. Biophys J. 2010;98:1344-1352.
65. Olinescu R, Kummerow F. Fibrinogen as an efficient antioxidant. J Nutr Biochem. 2001;12:162-169.
66. Feng YH, Hart G. In vitro oxidative damage to tissue-type plasminogen activator: a selective modification of the biological functions. Cardiovasc Res. 1995;30:255-261.
67. Upchurch GR Jr, Ramdev N, Walsh MT, Loscalzo J. Prothrombotic consequences of the oxidation of fibrinogen and their inhibition by aspirin. J Thromb Thrombolysis. 1998;5:9-14. (Pubitemid 28075248)
68. Metassan S, Charlton AJ, Routledge MN, Scott DJ, Ariëns RA. Alteration of fibrin clot properties by ultrafine particulate matter. Thromb Haemost. 2010;103:103-113.
69. Parastatidis I, Thomson L, Burke A, Chernysh I, Nagaswami C, Visser J, Stamer S, Liebler DC, Koliakos G, Heijnen HF, Fitzgerald GA, Weisel JW, Ischiropoulos H. Fibrinogen-chain tyrosine nitration is a prothrombotic risk factor. J Biol Chem. 2008;283:33846-33853.
70. Undas A, Szuldrzynski K, Stepien E, Zalewski J, Godlewski J, Tracz W, Pasowicz M, Zmudka K. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis. 2007;196:551-558.
71. Steinhubl SR. Why have antioxidants failed in clinical trials? Am J Cardiol. 2008;101:14D-19D.
72. Amelot AA, Tagzirt M, Ducouret G, Kuen L, Le Bonniec BF. Platelet factor 4 (CXCL4) seals blood clots by altering the structure of fibrin. J Biol Chem. 2007;282:710-720. (Pubitemid 47076616)
73. Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood. 2008;112:2810-2816.
74. Mutch NJ, Engel R, Uitte de Willige S, Philippou H, Ariëns RA. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood. 2010;115:3980-3988.
75. Smith SA, Choi SH, Davis-Harrison R, Huyck J, Boettcher J, Reinstra CM, Morrissey JH. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood. 2010;116:4353-4359.
76. Mutch NJ, Thomas L, Moore NR, Lisiak KM, Booth NA. TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. J Thromb Haemost. 2007;5:812-817. (Pubitemid 46563582)
77. Undas A, Stepien E, Tracz W, Szczeklik A. Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J Thromb Haemost. 2006;4:973-975.
78. Tsurupa G, Ho-Tin-Noe B, Anles-Cano E, Medved L. Identification and characterization of novel lysine-independent apolipoprotein(a)-binding sites in fibrin(ogen)αC-domains. J Biol Chem. 2003;278:37154-37159. (Pubitemid 37175230)
79. Jörneskog G, Egberg N, Fagrell B, Fatah K, Hessel B, Johnsson H, Brismar K, Blombäck M. Altered properties of fibrin gel structure in patients with IDDM. Diabetologia. 1996;39:1519-1523. (Pubitemid 26397359)
80. Dunn EJ, Ariëns RA, Grant PJ. The influence of type 2 diabetes on clot structure and function. Diabetologia. 2005;48:1198-1206. (Pubitemid 40909657)
81. Dunn EJ, Philippou H, Ariëns RA, Grant PJ. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia. 2006;49:1071-1080.
82. Jaleel A, Halvatsiotis P, Williamson B, Juhasz P, Martin S, Nair KS. Identification of Amadori-modified plasma proteins in type 2 diabetes and the effect of short-term intensive insulin treatment. Diabetes Care. 2005;28:645-652. (Pubitemid 40315326)
83. Jörneskog G, Hansson LO, Wallen NH, Yngen M, Blombäck M. Increased plasma fibrin gel porosity in patients with type I diabetes during continuous subcutaneous insulin infusion. J Thromb Haemost. 2003;1:1195-1201.
84. Sauls DL, Wolberg AS, Hoffman M. Elevated plasma homocysteine leads to alteration in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. J Thromb Haemost. 2003;1:300-306.
85. Lauricella AM, Quintana IL, Kordich LC. Effects of homocysteine thiol group on fibrin networks: another possible mechanism of harm. Thromb Res. 2002;107:75-79. (Pubitemid 35284429)
86. Jakubowski H. The molecular basis of homocysteine thiolactone mediated vascular disease. Clin Chem Lab Med. 2007;45:1704-1716. (Pubitemid 350232966)
87. Sauls DL, Lockhart E, Warren ME, Lenkowski A, Wilhelm SE, Hoffman M. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry. 2006;45: 2480-2487.
88. Undas A, Brozek J, Jankowski M, Siudak Z, Szczeklik A, Jakubowski H. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol. 2006;26: 1397-1404. (Pubitemid 44305388)
89. Ebbing M, Bønaa KH, Arnesen E, Ueland PM, Nordrehaug JE, Rasmussen K, Njølstad I, Nilsen DW, Refsum H, Tverdal A, Vollset SE, Schirmer H, Bleie Ø, Steigen T, Midttun Ø, Fredriksen A, Pedersen ER, Nygård O. Combined analyses and extended follow-up of two randomized controlled homocysteine-lowering B-vitamin trials. J Intern Med. 2010;268:367-382.
90. Undas A, Stepien E, Glowacki R, Tisonczyk J, Tracz W, Jakubowski H. Folic acid administration and antibodies against homocysteinylated proteins in subjects with hyperhomocysteinemia. Thromb Haemost. 2006;96:342-347. (Pubitemid 44377819)
91. Barua RS, Sy F, Srikanth S, Huang G, Javed U, Buhari C, Margosan D, Ambrose JA. Effects of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation. Arterioscler Thromb Vasc Biol. 2010;30:75-79.
92. Barua RS, Sy F, Srikanth S, Huang G, Javed U, Buhari C, Margosan D, Aftab W, Ambrose JA. Acute cigarette smoke exposure reduces clot lysis-association between altered fibrin architecture and the response to t-PA. Thromb Res. 2010;126:426-430.
93. Undas A, Topor-Madry R, Tracz W, Pasowicz M. Effect of cigarette smoking on plasma fibrin clot permeability and susceptibility to lysis. Thromb Haemost. 2009;102:1289-1291.
94. Williams S, Fatah K, Hjemdahl P, Blombäck M. Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid. Eur Heart J. 1998;19:1666-1672. (Pubitemid 28524185)
95. He S, Bark N, Wang H, Svensson J, Blombäck M. Effects of acetylsalicylic acid on increase of fibrin network porosity and the consequent upregulation of fibrinolysis. J Cardiovasc Pharmacol. 2009;53:24-29.
96. Fatah K, Beving H, Albage A, Ivert I, Blombäck M. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient? Eur Heart J. 1996;17:1362-1366. (Pubitemid 26306664)
97. Williams S, Fatah K, Ivert T, Blombäck M. The effect of acetyl salicylic acid on fibrin gel lysis by tissue plasminogen activator. Blood Coagul Fibrinolysis. 1995;6:718-725. (Pubitemid 26047201)
98. Ajjan RA, Standeven KF, Khanbhai M, Phoenix F, Gersh KC, Weisel JW, Kearney MT, Ariëns RA, Grant PJ. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol. 2009;29:712-717.
99. Bjornsson TD, Schneider DE, Berger H Jr. Aspirin acetylates fibrinogen and enhances fibrinolysis: fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther. 1989;250: 154-161. (Pubitemid 19194985)
100. Undas A, Sydor WJ, Brummel K, Musial J, Mann KG, Szczeklik A. Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation. 2003;107:17-20. (Pubitemid 36070925)
101. Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood. 2006;109:2285-2292. (Pubitemid 46425865)
102. Undas A, Brummel-Ziedins K, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol. 2005;25:287-294. (Pubitemid 40189147)
103. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A randomized trial of rosuvastatin in the prevention of venous thrombosis. N Engl J Med. 2009;360:1851-1861.
104. Undas A, Celinska-Lowenhoff M, Lowenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost. 2006;4:1029-1036.
105. Undas A, Topor-Madry R, Tracz W. Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l. Pol Arch Med Wewn. 2009;119:354-359.
106. Tehrani S, Mobarrez F, Antovic A, Santesson P, Lins PE, Adamson U, Henriksson P, Wallen NH, Jörneskog G. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res. 2010;126:e225-e231.
107. Bröijersen A, Hamsten A, Silveira A, Fatah K, Goodall AH, Eriksson M, Angelin B, Hjemdahl P. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII. Thromb Haemost. 1996;76:171-176. (Pubitemid 26285245)
108. Standeven KF, Ariëns RA, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes. 2002; 51:189-197. (Pubitemid 34517997)
109. Grant PJ. Beneficial Effects of metformin on haemostasis and vascular function in man. Diabetes Metab. 2003;29(4 Pt2):6S44-6S52. (Pubitemid 37187090)
110. Blombäck M, He S, Bark N, Wallen HN, Elg M. Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate. Br J Haematol. 2011;152:758-765.
111. He S, Blombäck M, Bark N, Johnsson H, Wallen NH. The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis. Thromb Haemost. 2010;103:1076-1084.
112. Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost. 2010;8:790-798.
113. Fatah K, Hamsten A, Blombäck B, Blombäck M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins, and coronary atherosclerosis. Thromb Haemost. 1992;68:130-135.
114. Fatah K, Silveira A, Tornvall P, Karpe F, Blombäck M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost. 1996;76: 535-540. (Pubitemid 26372007)
115. Undas A, Plicner D, Stepien E, Drwila R, Sadowski J. Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a), and homocysteine. J Thromb Haemost. 2007;5:1988-1990. (Pubitemid 47288965)
116. Bini A, Fenoglio J, Mesa-Tejada E, Kudryk B, Kaplan K. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Atherosclerosis. 1989;9:1038-1045.
117. Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, Ankri A, Blanchet B, Dumaine R, Gianetti J, Payot L, Weisel JW, Montalescot G. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol. 2006;26: 2567-2573. (Pubitemid 44607482)
118. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood. 2010;116:529-536.
119. Mills JD, Ariëns RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation. 2002;106:1938-1942. (Pubitemid 35176298)
120. Undas A, Wiek I, Stepien E, Zmudka K, Tracz W. Hyperglycemia is associated with enhanced thrombin formation, platelet activation and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care. 2008;31:1590-1595.
121. Undas A, Zalewski J, Krochin M, Siudak Z, Sadowski J, Pregowski J, Dudek D, Janion M, Witkowski A, Zmudka K. Altered plasma fibrin clot properties are associated with in-stent thrombosis. Arterioscler Thromb Vasc Biol. 2010;30:276-282.
122. Zalewski J, Undas A, Godlewski J, Stepien E, Zmudka K. No-reflow phenomenon after acute myocardial infarction is associated with reduced clot permeability and susceptibility to lysis. Arterioscler Thromb Vasc Biol. 2007;27:2258-2265. (Pubitemid 350287258)
123. Carter AM, Kirby D, Englyst NA, Ajjan RA, Bamford JM, Byrne C, Grant PJ. Fibrin structure/function in relation to stroke sub-types and post-stroke mortality. J Thromb Haemost. 2009;6(suppl):OC-WE-114 [Abstract].
124. Undas A, Podolec P, Zawilska K, Pieculewicz M, Jedliński I, Stêpień E, Konarska-Kuszewska E, Weglarz P, Duszyńska M, Hanschke E, Przewłocki T, Tracz W. Altered fibrin clot structure/function as a novel risk factor for cryptogenic ischemic stroke. Stroke. 2009;40:1499-1501.
125. Undas A, Slowik A, Wolkow P, Szczudlik A, Tracz W. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. Thromb Res. 2010;125:357-361.
126. Rooth E, Wallen NH, Blombäck M, He S. Decreased fibrin clot network permeability and impaired fibrinolysis in the acute and convalescent phase of ischemic stroke. Thromb Res. 2011;127:51-56.
127. Undas A, Nowakowski T, Cieoela-Dul M, Sadowski J. Altered plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thrombangiitis obliterans. Atherosclerosis. 2011;315:481-486.
128. Bhasin N, Parry DJ, Scott DJ, Ariëns RA, Grant PJ, West RM. Regarding "Altered fibrin clot structure and function in individuals with intermittent claudication." J Vasc Surg. 2009;49:1088-1089.
129. Guimaraes AHC, de Bruijne ELE, Lisman T, Dippel DW, Deckers JW, Poldermans D, Rijken DC, Leebeek FW. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br Haematol J. 2009;145: 115-120.
130. Bhasin N, Ariëns RA, West RM, Parry DJ, Grant PJ, Scott DJ. Altered fibrin clot architecture and function in the healthy first-degree relatives of subjects with intermittent claudication. J Vasc Surg. 2008;48: 1497-1503.
131. Curnow JL, Morel-Kopp MC, Roddie C, Aboud M, Ward CM. Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay. J Thromb Haemost. 2007;5:528-534. (Pubitemid 46680686)
132. Lisman T, de Groot PG, Meijers JCM, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005;15:1102-1105. (Pubitemid 40170881)
133. Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood. 2010;116:113-121.
134. Hoekstra J, Guimares AHC, Leebeek FW, Darwish Murad S, Malfliet JJ, Plessier A, Hernandez-Guerra M, Langlet P, Elias E, Trebicka J, Primignani M, Garcia-Pagan JC, Valla DC, Rijken DC, Janssen HL. European Network for Vascular Disorders of the Liver (EN-Vie): impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. Blood. 2010;115:388-395.
135. Undas A, Zawilska K, Ciesla-Dul M, Lehmann-Kopydłowska A, Skubiszak A, Ciepłuch K, Tracz W. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood. 2009;114:4272-4278.
136. Sjøland JA, Sidelmann JJ, Brabrand M, Pedersen RS, Pedersen JH, Esbensen K, Standeven KF, Ariëns RA, Gram J. Fibrin clot structure in patients with end-stage renal disease. Thromb Haemost. 2007;98: 339-345. (Pubitemid 47250237)
137. Undas A, Kolarz M, Kopeć G, Tracz W. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality. Nephrol Dial Transplant. 2008;23:2010-2015. (Pubitemid 351768150)
138. Undas A, Kaczmarek P, Sladek K, Stepien E, Skucha W, Rzeszutko M, Gorkiewicz-Kot I, Tracz W. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease: beneficial effects of simvastatin treatment. Thromb Haemost. 2009;102:1176-1182.
139. Salonen EM, Vartio T, Hedman K. Binding of fibronectin by the acute phase C-reactive protein. J Biol Chem. 1984;259:1496-1501. (Pubitemid 14104199)
140. Kwaoeny-Krochin B, Gluszko P, Undas A. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis. Thromb Res. 2010;126:e11-e16.
141. Bijlsma JW. Optimal treatment of rheumatoid arthritis: EULAR recommendations for clinical practice. Pol Arch Med Wewn. 2010;120: 347-353.